Does selegiline modify the progression of early Parkinson's disease? Results from a five-year study

European Journal of Neurology

Volumn 6, Issue 5, 1999, Pages 539-547

  Larsen, Jan P ^a,b   Boas, Jette ^c   Erdal, John Erik ^d  

^a STAVANGER UNIVERSITY HOSPITAL   (Norway)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^c GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

^d Orion Pharma ^*  (Norway)

Author keywords

Clinical progression; Parkinson's disease; Selegiline

Indexed keywords

ANTIPARKINSON AGENT; BENSERAZIDE PLUS LEVODOPA; SELEGILINE;

ADULT; AGED; ANGINA PECTORIS; ARTICLE; BACKACHE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DISEASE COURSE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DYSPEPSIA; GASTROINTESTINAL SYMPTOM; HALLUCINATION; HEART INFARCTION; HUMAN; INSOMNIA; LONG TERM CARE; MAJOR CLINICAL STUDY; MOTOR PERFORMANCE; MULTICENTER STUDY; NAUSEA; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYNCOPE; TREATMENT OUTCOME; VERTIGO;

EID: 0033385038     PISSN: 13515101     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1468-1331.1999.650539.x     Document Type: Article

References (37)

1. Alvord EC Jr, Forno LS, Kusske JA, Kauffman RJ, Rhodes JS, Goetowski CR (1974). The pathology of parkinsonism: a comparison of degenerations in cerebral cortex and brainstem. In: Advances in Neurology (vol. 5) (editors, McDowell FH, Barbeau A). New York, Raven Press. pp 175-193.
2. Ben-Shlomo B, Churchyard A, Head J, Hurwitz B, Overstall P, Oekelford J, Lees AJ (1998). Investigation by Parkinson's Disease Research Group of United Kingdom into excess mortality seen with combined levodopa and selegiline treatment in patients with early, mild Parkinson's disease: further results of randomized trial and confidential inquiry. BMJ 316:1191-1196.
3. Birkmayer W, Knoll J, Riederer P, Youdim MBH, Hars V, Marton J (1985). Increased life expectancy resulting from addition of l-deprenyl to Madopar treatment in Parkinson's disease: a long-term study. J Neural Transm 64:113-127.
4. Block G, Liss C, Reines S, Irr J, Nibbelink D (1997). Comparison of immediate-release and controlled-release carbidopa/levodopa in Parkinson's disease. A multi-centre five year study. Eur Neurol 37:23-27.
5. Brannan T, Yahr MD (1995). Comparative study of selegiline plus L-dopa-carbidopa versus dopa-carbidopa alone in the treatment of Parkinson's disease. Ann Neurol 37:95-98.
6. Bravi D, Mouradian MM, Roberts JW, Davis TL, Sohn YH, Chase TN (1994). Wearing-off fluctuations in Parkinson's disease: contributions of postsynaptic mechanisms. Ann Neurol 36:27-31.
7. Brown HK, Kempton RA (1994). The application of REML in clinical trials. Stats Med 13:1601-1617.
8. Cohen G, Pasik P, Cohen B, Leist A, Mytilincou C, Yahr MD (1984). Pargyline and deprenyl prevent the neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in monkeys. Eur J Pharmacol 106:209-210.
9. Cohen G, Spina MB (1989). Deprenyl suppresses the oxidant stress associated with increased dopamine turnover. Ann Neurol 26:689-690.
10. Collet D (1994). In: Modelling Survival Data in Medical Research. London, Chapman & Hall.
11. 11C]deprenyl. Neurology 46:A453.
12. Fabbrini G, Mouradian MM, Juncos JL, Schlegel J, Mohr E, Chase TN (1988). Motor fluctuations in Parkinson's disease: central pathophysiological mechanisms, part I. Ann Neurol 24:366-371
13. Fahn S, Elton RL (1987). Members of the UPDRS Development Commitee. Unified Parkinson's Disease Rating Scale. In: Recent Developments in Parkinson's Disease (editors Fahn S, Marsden CD, Calne DB. Lieberman A). Florham Park, NJ, MacMillan Health Care Information, pp. 153-163.
14. Fowler JS, Volkow ND, Logan J, Wang GJ, MacGregor RR, Schyler D, et al. (1994). Slow recovery of human brain MAO-B after L-deprenyl (selegiline) withdrawal. Synapse 18:86-93.
15. Golbe LI, Langston JW. Shoulson I (1990). Selegiline and Parkinson's disease. Protective and symptomatic considerations. Drugs 39:646-651.
16. Hoehn MH, Yahr MD (1967). Parkinsonism: onset, progression and mortality. Neurology 17:427-442.
17. Jannrich RI, Schluchtcr MD (1986). Unbalanced repeated-measures models with structured covariance matrices. Biometrics 42:805-820.
18. Kieburtz K and the Parkinson Study Group (1998). Combination of levodopa and selegiline in the DATATOP study. Eur J Neurol 5(suppl. 3):245.
19. Larsen JP, Boas J and the Norwegian-Danish Parkinson Study Group (1997). The effects of early selegiline therapy on long-term levodopa treatment and parkinsonian disability. An interim analysis of a Norwegian-Danish five-year study. Move Disord 12:175-182.
20. Leenders KL, Palmer AJ, Quinn N, Clark JC, Firnau G, Garnett ES, et al. (1986). Brain dopamine metabolism in patients with Parkinson's disease measured with positron emission tomography. J Neurol Neurosurg Psychiat 49:853-860.
21. Lees AJ and the Parkinson's Disease Research Group of the United Kingdom (1995). Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. BMJ 311:1602-1607.
22. Marsden CD, Parkes JD, Quinn N (1982). Fluctuations of disability in Parkinson's disease-clinical aspects, In: Movement Disorders (editors Marsden CD, Fahn S). London, Butterworths. pp. 96-122.
23. Myllylä VV, Sotaniemi KA, Hakulinen P, Mäki-Ikola O, Heinonen FH (1997). Selegiline as the primary treatment of Parkinson's disease - a long-term double-blind study. Acta Neurol Scand 95:211-218.
24. Nutt JG, Hammerstad JP, Gancher ST (1992). In: Parkinson's Disease. 100 Maxims. London, Edward Arnold.
25. Olanow CW (1993). A radical hypothesis for neurodegeneration. TINS 16:439-444.
26. Olanow CW, Hauser RA, Gauger L, Malapira T, Koller W, Hubble J, et al. (1995), The effects of deprenyl and levodopa on the progression of Parkinson's disease. Ann Neurol 38:771-777.
27. Olanow CW, Myllylä VV, Sotaniemi KA, Larsen JP, Pålhagen S, Przuntek H, et al. (1998). Effect of selegiline on mortality in patients with Parkinson's disease. A meta-analysis. Neurology 51:825-830.
28. Parkinson Study Group (1996). Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP patients requiring levodopa. Ann Neurol 9:37-45.
29. Relja MA. Heinonen EH, Kilkku O, Måki-Ikola O, Rinne UK (1997). The symptomatic effect of selegiline on parkinsonian disability is lost in one week: a quantitative assessment. Move Disord 12(suppl 1):122.
30. Salo PT, Tatton WG (1992). Deprenyl reduces the death of motoneurons caused by axotomy. J Neurosci Res 31:394-400.
31. Schwab RS, England AC (1969). Projection technique for evaluating surgery in Parkinson's disease. In: Third Symposium on Parkinson's Disease (editors Gillingham FJ, Donaldson Mc). Edinburgh, E&S Livingstone.
32. Shaw KM, Lees AJ, Stern GM (1980). The impact of treatment with levodopa on Parkinson's disease. Quart J Med 49:283-293.
33. Spencer SE, Wooten GF (1984). Altered pharmacokinetics of L-dopa metabolism in rat striatum deprived of dopaminergic innervation. Neurology 34:1105-1108.
34. Tandberg E, Larsen JP, Nessler EG, Riise T, Aarli JA (1995). The epidemiology of Parkinson's disease in the county of Rogaland, Norway. Move Disord 10:541-549.
35. Tatton WG, Greenwood CE (1991), Rescue of dying neurons: a new action for deprenyl in MPTP parkinsonism. J Neurosci Res 30:666-677.
36. Thorogood M, Armstrong B, Nichols T, Hollowell J (1998). Mortality in people taking selegiline: observational study. BMJ 317:252-254.
37. Vingerhoets FJG, Schulzer M, Calne DB, Snow BJ (1997). Which clinical signs of Parkinson's disease best reflect the nigrostriatal lesion? Ann Neurol 41:58-64.